Mon, Jul 14, 2014, 10:37 AM EDT - U.S. Markets close in 5 hrs 23 mins


% | $
Quotes you view appear here for quick access.

Smith & Nephew plc Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • by fretfulporpentine Jun 22, 2014 12:28 AM Flag

    Now that Shire PLC (SHPG) is in play is SNN next in line? I saw at least three articles last week.

    (1) Needham & Company Comments on Sector Implications Amid Medtronic (MDT)/Covidien (COV) Megadeal 6/16/2014
    ... think Smith & Nephew (NYSE: SNN) has become increasingly attractive to suitors and that it is all but inevitable that Stryker Corp. (NYSE: SYK) attempts to acquire SNN. However, they note SNN may not be a willing seller, and we think SYK could end up in a similar situation as Pfizer (PFE) after it was spurned by AstraZeneca (AZN).

    (2) Smith & Nephew (SNN) Still Seen as Takeover Target Amid Medtronic/Covidien Deal - Summer Street
    8:49 AM ET, 06/16/2014 - Street Insider
    Summer Street analyst Mark Landy reiterated a Buy rating and $112 price target on Smith & Nephew (NYSE: SNN) saying they continue to view the company as a prime acquisition target despite this weekend's Medtronic (NYSE: MDT)/Covidien (NYSE: COV) deal. The firm feels the deal pushes Stryker Corp. (NYSE: SYK) and Boston Scientific Corp.

    UPDATE 1-Medtronic's Covidien deal raises bar for rivals to merge
    5:04 PM ET, 06/16/2014 - Reuters
    UK-based Smith & Nephew Plc, which has already attracted takeover interest from companies seeking better tax rates overseas, remains high on the list of targets, they said. Device makers such as Boston Scientific Corp should feel more pressure to get bigger or face being left out in the cold.

    I have taken a small nibble and am awaiting developments. Any comments from other shareholders?

    Sentiment: Hold

87.64-0.12(-0.14%)10:35 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.